On Thursday, in the course of current trade, Shares of USA Technologies, Inc. (NASDAQ:USAT), dropped -4.74%, and is now trading at $3.24.
USA Technologies, declared that J. Duncan Smith, chief financial officer, and Dave DeMedio, chief services officer, will present at the 6th Annual Craig-Hallum Alpha Select Conference on Thursday, September 17, 2015 at the Convene Conference Center in New York, NY.
USA Technologies, Inc. provides wireless networking, cashless transactions, asset monitoring, and other value-added services principally to the small ticket unattended retail markets in the United States and internationally.
During an Afternoon trade, Shares of Christopher & Banks Corporation (NYSE:CBK), dipped -2.76%, and is now trading at $1.41.
Christopher & Banks Corporation, stated results for the thirteen week period ended August 1, 2015.
Results for the Thirteen Week Period Ended August 1, 2015
- Net sales totaled $94.0 million, as contrast to $106.6 million for the thirteen weeks ended August 2, 2014. During the quarter, the Company operated an average of 4.4% fewer stores than during the comparable period last year, reflecting its MPW store conversion strategy; offset to some extent by new store openings, primarily outlets.
- Same-store sales reduced 12.4% in the thirteen weeks ended August 1, 2015, as contrast to the thirteen weeks ended August 2, 2014; this follows a 4.7% same-store sales improvement in last year’s second quarter.
- Gross margin was 32.9% contrast to 35.3% in the second quarter of fiscal 2014.
- Operating loss was $1.7 million for the thirteen week period ended August 1, 2015. This compares to operating income of $3.3 million in the second quarter of fiscal 2014.
- Net loss totaled $0.7 million, or ($0.02) per share. Net income for the thirteen weeks ended August 2, 2014 totaled $3.4 million, or $0.09 per diluted share.
Christopher & Banks Corporation, through its auxiliaries, operates as a retailer of womens apparel and accessories in the United States. The company designs, sources, and sells womens apparel and accessories to customers ranging in age from 45 to 60. Its stores offer womens apparel compriseing of knit tops, woven tops, jackets, sweaters, skirts, denim bottoms, bottoms made of other fabrics, leisure wear, and dresses in missy, petite, and women sizes, in addition to jewelry and accessories.
Finally, Biocept Inc (NASDAQ:BIOC), gained 1.12% Thursday.
Biocept, a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, declares the allowance of U.S. Patent 9,128,082 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The patent covers the use of antibodies in the capture of cells such as circulating tumor cells (CTCs) from blood, in addition to other biological fluids, using the company’s patented microchannel capture device. Biocept’s antibody capture cocktail together with the microchannel are key components of the company’s Cell Enrichment and Extraction (CEE™) platform, providing for the high-efficiency capture, visualization and microscopic analysis of targeted cells obtained from a patient blood sample and used by physicians for medical decision making.
Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept, said, “The issuance of this patent expands Biocept’s patent portfolio to comprise the use of antibodies in the capture of cancer cells in combination with our microchannel for which multiple U.S. and international patents have been granted. Our antibody cocktail is a key part of our patented and proprietary method to capture and analyze cells from a wide variety of tumor types. In addition, this patent expands our IP protection for the use of a simple blood sample, and other biological sample types, in obtaining valuable biomarker information that can be used by physicians to personalize treatment of individual patients.”
Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
